Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma
Background:
The incidence of non-alcoholic steatohepatitis (NASH) is increasing worldwide and a poorly defined subset of patients develops end-stage liver disease and hepatocellular carcinoma (HCC). Differences in the biological behaviour, tumour characteristics, associated risk factors, treatment outcomes and overall survival of patients with NASH-HCC remain poorly defined. The aim of this study was to determine and analyze these differences in a large clinical cohort to guide treatment decisions.
Methods:
1119 patients with HCC treated in an 11 year period at the University Medical Centre of the Johannes Gutenberg University Mainz were retrospectively analyzed.
Results:
Patients with NASH-HCC (n = 45) were older (67.6 vs. 65 years), had an increased frequency of the metabolic syndrome and complications with a higher incidence of obesity (31.1% vs. 14.7%), type II diabetes mellitus (66.7% vs. 37.85%), a higher rate of myocardial infarction (13.3% vs. 4.8%) and apoplectic stroke (8.9% vs. 2.1%) (all p
Source: BMC Cancer - Category: Cancer & Oncology Authors: Arndt WeinmannYvonne AltSandra KochCarina NellesChristoph DüberHauke LangGerd OttoTim ZimmermannJens MarquardtPeter GalleMarcus WörnsJörn Schattenberg Source Type: research
More News: Alcoholism | Cancer | Cancer & Oncology | Carcinoma | Diabetes | Diabetes Mellitus | Eating Disorders & Weight Management | Endocrinology | Heart Attack | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Metabolic Syndrome | Obesity | Stroke | Study | Urology & Nephrology